#semaglutide

#semaglutide

Semaglutide mimics a hormone that is released when we eat, tricking the brain into thinking we are full and dialing down appetite.

Novo Nordisk, creator of the mega-hit drug Ozempic, has seen a loss of nearly $100 billion in market value due to collapsing sales and missed forecasts.

Approximately 40% of the weight lost from taking semaglutide -- a type of weight-loss medication known as a GLP-1 -- comes from lean mass, including muscle.

This suggests that these nerve cells control the beneficial effects of semaglutide. We have therefore identified a specific group of nerve cells that is necessary for the effects that semaglutide has on weight and appetite, but which does not appear to contribute to any significant extent to side effects such as nausea.

After 72 weeks, nearly 63 percent of those who received semaglutide injections and around 34 percent of those on placebo shots saw their liver condition improve.